You are now leaving this site and you'll be redirected to the Interbrand Global website.

Services

Regulatory Strategy

Expert regulatory consultation guiding clients from name development through regulatory submission. Services include name safety evaluation, prescription audits, FMEA (Failure Mode Effects Analysis), diagnostic studies, and name submission report development.

Work

Pharma brand naming for VPRIV

Strategic naming in pharma

Pharma brand naming for Bydureon

Pharma brand naming for XALKORI

Expressing innovation through name

Analytics for safety & success

Views

FDA news: Challenges in naming biosimilars

Suzanne Martinez

6 Challenges to Brand Naming in Pharma

Suzanne Martinez

4 Things You Need to Know About the FDA's Drug Naming Guide

John Breen and Lillian Smith

Rx to OTC: What It Means for Your Product's Brand Equity

Ramya Kartikeyan

Looking at the future of biosimilars

Biosimilars: Coming of age?

The right prescription of patent expiration

Key takeaways from the Social Media for Pharma Conference

News

The art & science of naming drugs

November 29, 2016

International Business Times explores drug names with InterbrandHealth

CNBC asks InterbrandHealth about challenges in drug naming

Wes Wilkes on the new face of pharma marketing

February 13, 2015

InterbrandHealth creative experts discuss drug naming

December 8, 2014

R. John Fidelino talks Prozac in New York Times Retro Report

September 21, 2014

InterbrandHealth on the art & science of drug naming

August 22, 2014

Slate: drug naming

August 22, 2013

Growth starts here